指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

基于肾脏行动小组(KAT-AKI)对住院急性肾损伤患者实施个体化推荐:一项随机对照试验的方案与早期数据

Personalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial.
指南 / 共识 · BMJ Open · 2023-04-17
一句话结论KAT-AKI试验:实时电子预警触发医师与药师团队,在急性肾损伤检出后立即向主管团队提供个体化推荐,评估其对14天内AKI进展、透析与死亡复合终点的影响。

KAT-AKI是一项多中心、研究者盲法的随机对照试验,在两家美国医院系统的8家医院计划3年内纳入4000例住院AKI患者,随机分为预警组(实时接收由医师和药师团队制定的个体化推荐)与常规护理组(推荐仅记录用于后续分析)。主要终点为随机化后14天内AKI进展、透析与死亡的复合终点,关键次要终点为随机化后24小时内主管团队对推荐的执行百分比。早期数据显示8.5个月已纳入500例,其中三分之二在普通病房、17.8%在ICU;几乎所有参与者至少被推荐一项诊断性干预,51.6%被推荐停用或调整药物剂量;从AKI预警到随机化的中位时间为28分钟(IQR 15.8-51.5)。

要点

  • KAT-AKI为多中心随机对照试验,计划在8家医院纳入4000例住院AKI患者,随机分为实时个体化推荐组与常规护理组。
  • 推荐由医师和药师团队实时独立审阅病历后联合制定,覆盖诊断、容量、钾、酸碱和药物五个领域。
  • 主要终点为随机化后14天内AKI进展、透析与死亡的复合终点;关键次要终点为24小时内推荐执行百分比。
  • 早期500例中三分之二在普通病房、17.8%在ICU;几乎所有参与者至少被推荐一项诊断性干预,51.6%被推荐停用或调整药物剂量。
  • 从AKI预警到随机化的中位时间为28分钟(IQR 15.8-51.5),提示该干预可在检出后早期实施。

适用人群与场景

  • 住院期间经实时电子AKI预警系统检出的急性肾损伤患者。
  • 早期500例中,预警时三分之二位于普通病房,17.8%位于重症监护室(ICU)。

处置流程与药物剂量

  • 实时电子AKI预警系统通知由医师和药师组成的专职团队。
  • 该团队实时独立审阅病历、筛查合格性,并联合制定覆盖诊断、容量、钾、酸碱和药物五个领域的推荐。
  • 预警组将推荐送达主管团队;常规护理组仅记录推荐用于后续分析。

研究设计与关键结果

  • KAT-AKI为多中心、研究者盲法随机对照试验,在两家美国医院系统的8家医院开展,计划2021年11月1日至2024年11月1日3年内纳入4000例患者。
  • 主要终点为随机化后14天内AKI进展、透析与死亡的复合终点;关键次要终点为随机化后24小时内主管团队对推荐的执行百分比。
  • 8.5个月内已纳入500例;预警时三分之二在普通病房,17.8%在ICU。
  • 几乎所有参与者至少被推荐一项诊断性干预;51.6%被推荐停用或调整药物剂量。
  • 从AKI预警到随机化的中位时间为28分钟(IQR 15.8-51.5)。

证据类型、等级与局限

  • 证据类型:随机对照试验的方案与早期数据。
  • 试验注册号:NCT04040296。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Although studies have examined the utility of clinical decision support tools in improving acute kidney injury (AKI) outcomes, no study has evaluated the effect of real-time, personalised AKI recommendations. This study aims to assess the impact of individualised AKI-specific recommendations delivered by trained clinicians and pharmacists immediately after AKI detection in hospitalised patients.

METHODS AND ANALYSIS: KAT-AKI is a multicentre randomised investigator-blinded trial being conducted across eight hospitals at two major US hospital systems planning to enrol 4000 patients over 3 years (between 1 November 2021 and 1 November 2024). A real-time electronic AKI alert system informs a dedicated team composed of a physician and pharmacist who independently review the chart in real time, screen for eligibility and provide combined recommendations across the following domains: diagnostics, volume, potassium, acid-base and medications. Recommendations are delivered to the primary team in the alert arm or logged for future analysis in the usual care arm. The planned primary outcome is a composite of AKI progression, dialysis and mortality within 14 days from randomisation. A key secondary outcome is the percentage of recommendations implemented by the primary team within 24 hours from randomisation. The study has enrolled 500 individuals over 8.5 months. Two-thirds were on a medical floor at the time of the alert and 17.8% were in an intensive care unit. Virtually all participants were recommended for at least one diagnostic intervention. More than half (51.6%) had recommendations to discontinue or dose-adjust a medication. The median time from AKI alert to randomisation was 28 (IQR 15.8-51.5) min.

ETHICS AND DISSEMINATION: The study was approved by the ethics committee of each study site (Yale University and Johns Hopkins institutional review board (IRB) and a central IRB (BRANY, Biomedical Research Alliance of New York). We are committed to open dissemination of the data through clinicaltrials.gov and sharing of data on an open repository as well as publication in a peer-reviewed journal on completion.

TRIAL REGISTRATION NUMBER: NCT04040296.

来源:BMJ Open,查看原文。版权归原作者所有。

参考来源

  1. Aklilu AM, O'Connor KD, Martin M, et al. Personalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial. BMJ Open. 2023. PMID: 37068906. doi:10.1136/bmjopen-2023-071968

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。